AbbVie Inc.
NYSE:ABBVDrug Manufacturers - General
-$4.65 today
- Market cap
- $505.47B
- Beta
- 0.31
- P/E (TTM)
- 105.6
- EPS (TTM)
- $2.05
- Dividend yield
- 3.11%
Volume 4.73M
Average 6.47M
ABBV Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
AbbVie Inc.NYSE: ABBV
Accumulated OCI · Q2 FY2026 · quarter ended Jun 2026
Accumulated OCI remains negative
Q2 FY2026 Accumulated OCI was -$1.16B, compared with -$1.54B a year earlier.
Context
- Accumulated OCI amounted to 0.9% of total assets at the end of Q2 FY2026, down 0.3 pp from a year earlier.
- Accumulated OCI grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +24.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- (1.14B) USD
- Year-over-year change
- +40.6%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.14B) | +40.6% |
| FY2024 | 2024-12-31 | (1.93B) | +16.5% |
| FY2023 | 2023-12-31 | (2.31B) | -4.8% |
| FY2022 | 2022-12-31 | (2.2B) | +24.1% |
| FY2021 | 2021-12-31 | (2.9B) | — |
Accumulated OCI vs competitors
How ABBV compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +24.7% is the 5th highest of 10, against a peer median of +17.0%.
- Accumulated OCI amounts to 0.9% of total assets for ABBV, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.98B USD | -3.1% | — | 1.7% | |
| Jun 2026 | £1.32B GBP | -17.1% | — | 2.1% | |
| Jun 2026 | $1.21B USD | +538.5% | — | 1.0% | |
| Jun 2026 | -$119M USD | +78.1% | — | 0.1% | |
| Jun 2026 | -$1.16B USD | +24.7% | — | 0.9% | |
| Jun 2026 | -$1.29B USD | +17.0% | — | 1.5% | |
| Jun 2026 | -$2.76B USD | +25.7% | — | 1.9% | |
| Jun 2026 | -$3.94B USD | +27.3% | — | 3.0% | |
| Jun 2026 | -$7.22B USD | +14.5% | — | 3.6% | |
| Sep 2026 | -$13.77B USD | +9.7% | — | 7.0% | |
| Peer median (excluding ABBV) | — | +17.0% | — | 1.9% | |
Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9.75B | 9.2B | 12.81B | 5.52B | 5.23B |
| Short-term Investments | 84M | 28M | 2M | 31M | 28M |
| Net Receivables | 9.98B | 11.25B | 11.16B | 10.92B | 12.59B |
| Inventory | 3.13B | 3.58B | 4.1B | 4.18B | 4.95B |
| Other Current Assets | 226M | 4.4B | 4.93B | 4.93B | 6.27B |
| Total Current Assets | 27.93B | 28.46B | 33B | 25.58B | 29.06B |
| Property, Plant & Equipment (Net) | 5.11B | 4.94B | 4.99B | 5.13B | 6.37B |
| Goodwill | 32.38B | 32.16B | 32.29B | 34.96B | 35.64B |
| Intangible Assets | 75.95B | 67.44B | 55.61B | 60.07B | 52.64B |
| Long-term Investments | 277M | 241M | 304M | 279M | 299M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.88B | 5.57B | 8.51B | 9.14B | 9.95B |
| Total Non-current Assets | 118.6B | 110.34B | 101.71B | 109.58B | 104.9B |
| Total Assets | 146.53B | 138.81B | 134.71B | 135.16B | 133.96B |
| Account Payables | 2.88B | 2.93B | 3.69B | 2.95B | 3.59B |
| Short-term Debt | 12.67B | 4.3B | 7.19B | 6.8B | 8.75B |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 17.85B | 20.93B | 25.16B | 27.01B | 25.63B |
| Total Current Liabilities | 35.19B | 29.54B | 37.84B | 38.75B | 43.29B |
| Long-term Debt | 64.16B | 59.12B | 52.17B | 60.34B | 59.61B |
| Deferred Tax Liabilities | 8.98B | 8.69B | 8.63B | 7.63B | 7.96B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 22.02B | 23.4B | 24.91B | 24.38B | 25.62B |
| Total Non-current Liabilities | 95.9B | 91.98B | 86.47B | 93.05B | 93.9B |
| Total Liabilities | 131.09B | 121.52B | 124.31B | 131.8B | 137.19B |
| Common Stock | 18M | 18M | 18M | 18M | 18M |
| Retained Earnings | 3.13B | 4.78B | (1B) | (7.9B) | (15.49B) |
| Accumulated OCI | (2.9B) | (2.2B) | (2.31B) | (1.93B) | (1.14B) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 28M | 33M | 37M | 39M | 42M |
| Total Equity | 15.44B | 17.29B | 10.4B | 3.36B | (3.23B) |
| Total Debt | 77.58B | 64.19B | 60.12B | 67.84B | 69.07B |
| Net Debt | 67.83B | 54.99B | 47.31B | 62.32B | 63.84B |
AbbVie Inc.
NYSE:ABBV
Intrinsic Alpha fair value
Locked
Current Price
$285.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.